Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
UVE Universal Insurance Holdings Inc
UNTY Unity Bancorp Inc
MCVT Mill City Ventures III Ltd
PAVM PAVmed Inc
SPG Simon Property Group Inc
AAPL Apple Inc
BBY Best Buy Co Inc
METC Ramaco Resources Inc
MJNA Medical Marijuana Inc
Go

Financials : Banks | Large Cap ValueCompany profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Premarket

Last Trade
Delayed
$29.81
-0.13 (-0.43%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.94
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
1,806

10-day average volume:
59,031,548
1,806

UPDATE: Health companies start reporting earnings next week: Here are 3 things to keep in mind

6:58 am ET July 15, 2019 (MarketWatch)
Print

By Sarah Toy

These are the trends that will shape how the market reacts to earnings

Health companies will begin reporting second-quarter earnings next week, starting with two Dow components, Johnson & Johnson and UnitedHealth Group Inc.

It has been a tumultuous few months for managed-care companies, pharmaceutical companies and biotechs. Fears around "Medicare for all" (http://www.marketwatch.com/story/bernie-sanders-unveils-new-version-of-his-medicare-for-all-plan-2019-04-10) weighed on earnings last quarter. UnitedHealth (UNH) , facing investor anxiety about the implementation a single-payer system, saw its shares drop sharply in April (http://www.marketwatch.com/story/unitedhealth-stock-falls-despite-earnings-beat-signaling-investor-jitters-over-medicare-for-all-2019-04-16) even after the company beat Wall Street expectations and boosted full-year guidance. Shares of other insurers and managed-care companies also fell at the time (http://www.marketwatch.com/story/health-care-stocks-keep-getting-hammered-wall-street-says-this-is-why-2019-04-17), and biopharma stocks followed suit (http://www.marketwatch.com/story/health-care-drama-has-now-spread-to-biopharma-stocks-2019-04-18).

Some of those fears have since dissipated and health stocks have mostly recovered to their pre-April levels. But there's still some unease about where the health regulatory landscape is headed, and pharmaceutical companies are still facing questions about their long-term growth potential.

Here are three big things on investors' minds as earnings season kicks off this time around.

Potential changes in health policy

Although it seems that the worst is over for health stocks, the fate of the Affordable Care Act remains uncertain, with 20 state attorneys challenging the law's constitutionality without its penalty on patients without coverage.

Change could also be coming for drug pricing. The Trump administration has vowed it will drive down drug costs, but how and when is still up in the air. The administration has made several proposals -- requiring drugmakers to disclose drug prices in television ads, overhauling the current rebates system and mulling an executive order allowing the U.S. to buy drugs based on the lowest price paid by other countries -- but investors aren't sure which, if any, of those will stick. The administration said on Thursday it would be withdrawing its plan to overhaul the rebates that drugmakers give to middlemen in Medicare (http://www.marketwatch.com/story/stocks-of-drug-distributors-and-pbm-owners-surge-after-trump-administration-pulls-rebate-proposal-2019-07-11), and a federal judge on Monday blocked the plan to require pharmaceutical companies to disclose drug prices in TV ads.

"In the near term... we expect the focus on drug pricing reform (congressional action and/or potential presidential executive orders) will likely dictate sentiment and complicate setups into the print themselves. As such, we expect the sector will be volatile over the next couple of weeks," UBS analyst Carter Gould wrote in a Thursday note on second-quarter biotech earnings to clients.

Read: This would be the worst-case scenario for health stocks, according to UBS (http://www.marketwatch.com/story/this-would-be-the-worst-case-scenario-for-health-companies-according-ubs-2019-06-19)

Patent expirations and generic competition

Many big biopharma companies rely on just one or two drugs for a big chunk of their revenue. Now they're facing the twin demons of patent expiration and generic competition. This was a big theme last earnings season and is expected to loom large over second-quarter earnings as well.

A prime example: AbbVie Inc.'s (ABBV) top-selling drug Humira, which brought in 61% of the company's revenue in 2018, is facing increasing competition in Europe. The drugmaker warned investors that 2019 sales would drop after competitors like Mylan NV (MYL) and Amgen Inc. (AMGN) began selling lower-cost biosimilars of the drug in Europe in October.

Sales of AbbVie's Humira fell 5.6% last quarter, but management assured investors (http://www.marketwatch.com/story/abbvie-execs-say-biosimilar-competition-to-humira-is-eroding-profits-but-we-have-a-plan-2019-04-25) that the company's pipeline would more than plug up any holes that biosimilar competition to Humira might leave. AbbVie has said the competition will likely reduce overall Humira sales by $2 billion this year.

M&A wave

Investors did not expect that AbbVie would expand its portfolio by acquiring troubled pharmaceutical giant Allergan Plc (http://www.marketwatch.com/story/allergan-acquisition-is-a-major-bailout-for-shareholders-according-to-analysts-2019-06-25)(AGN) . The deal, announced in late June and worth about $63 billion, adds several big-name cosmetic treatments, like anti-wrinkle injectable Botox and dermal filler Juvéderm, to the AbbVie line-up.

The acquisition came shortly after Pfizer Inc. (PFE) agreed to buy cancer-therapy biotech Array BioPharma Inc (http://www.marketwatch.com/story/pfizer-to-buy-cancer-dug-maker-array-biopharma-for-1064-billion-2019-06-17).(ARRY) for $10.64 billion in cash. Earlier that month, Merck & Co. Inc. (MRK) bought Tilos Therapeutics Inc (http://www.marketwatch.com/story/merck-to-buy-cancer-treatment-biotech-tilos-therapeutics-for-up-to-773-million-2019-06-10). for $773 million, and in May, Merck agreed to acquire Peloton Therapeutics Inc (http://www.marketwatch.com/story/merck-to-acquire-peloton-therapeutics-for-upfront-payment-of-105-billion-in-cash-2019-05-21). for around $1.1 billion. In January, Bristol-Myers Squibb Co. (BMY) kicked off the new year by announcing it would acquire Celgene Corp (http://www.marketwatch.com/story/bristol-myers-squibb-agrees-to-acquire-celgene-for-about-74-billion-2019-01-03).(CELG) for an estimated $74 billion.

This wave of megamergers comes as large biopharmaceutical companies look for ways to generate growth. And investors should expect more of these; last month, Moody's said M&A activity is set to rise (http://www.marketwatch.com/story/amgen-biogen-gilead-and-novo-nordisk-have-very-high-capacity-for-ma-says-moodys-2019-06-13) and named Amgen Inc. (AMGN) , Biogen Inc. (BIIB) , Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO) as likely acquirers. (http://www.marketwatch.com/story/abbvie-execs-say-biosimilar-competition-to-humira-is-eroding-profits-but-we-have-a-plan-2019-04-25)

Read: J&J earnings preview: Wall Street is still optimistic despite company's legal issues (http://www.marketwatch.com/story/jj-earnings-preview-wall-street-is-still-optimistic-despite-companys-legal-issues-2019-07-10)

Also: UnitedHealth stock has bounced back after a rough first quarter. Will its positive streak continue? (http://www.marketwatch.com/story/unitedhealth-stock-has-bounced-back-after-a-rough-first-quarter-will-its-positive-streak-continue-2019-07-11)

-Sarah Toy; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 15, 2019 06:58 ET (10:58 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.